501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Presents FAIMS Marijuana Breathalyzer Technology at
the Texas Impaired Driving Forum
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia --
February 24, 2022 -- InvestorsHub NewsWire -- Cannabix Technologies
Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer of marijuana breathalyzer devices for law enforcement and
the workplace reports that Cannabix's Dr. Jared Boock recently
presented key innovations made by Cannabix and its FAIMS based
detection technology, a first-of-its-kind device, at the Texas
Impaired Driving Forum, held by Texas A&M Transportation
Institute (TTI) on February 23rd.
In addition, Dr. Boock
provided technical background on sampling and detection methods for
?9-tetrahydrocannabinol ("THC")
in breath and why FAIMS (a specific method of ion filtering related
to mass spectrometry) allows for a powerful portable instrument
with the specificity of mass spectrometry. The advent of the Cannabix FAIMS
based marijuana breath detection technology comes at a time when
legislators across the United States and elsewhere are grappling
with the ever-increasing problem of drugged-driving.
Dr. Jared Boock, Senior Analytical
Chemist stated, "It is very evident that legislators, scientists,
law enforcement and policy makers are seeking better ways to equip
officers with the new tools needed to provide, fair, fast and
non-invasive drug screening capability at roadside. The cannabis
industry and law-makers are at a virtual standstill until tools
like the ones we are developing come to market. We are very pleased
to have had the opportunity to discuss some of the powerful
capabilities of FAIMS technology, and how it can cut through the
complexities of human breath and achieve specific analyte detection
in semi-volatile species like THC. THC quantities are a million
times lower in breath than detection of alcohol in breath -
diligence and innovation have been at the cornerstone of the
development of our various technologies."
The Texas Impaired Driving Forum
attracted attendees from across the state of Texas and elsewhere.
This year's program had a number of speakers related to the topic
of cannabis and driving. The audience consisted of traffic safety
stakeholders specialize in fields such as prosecution, judicial
review, probation, law enforcement, education/advocacy, prevention,
treatment, and highway safety.
Cannabix is using its FAIMS
technology to detect THC, a non-volatile compound, in breath.
Breath testing for THC would allow law enforcement to quickly and
practically identify recent marijuana use that better aligns with
impairment than other methods. The Cannabix device has been
designed and built in a series of modules that together allow for
sample intake, ionization, filtering and detection - all done under
atmospheric pressure. Cannabix is conducting in-house testing of
the FAIMS Detection Unit in both portable and laboratory
modes.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities. The Company is not currently
selling commercial breathalyzers. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.